Research compound encyclopedia
Incretin & metabolic research compounds
GLP-1, GIP, glucagon and amylin pathway compounds, plus metabolic modulators. Several are approved medicines elsewhere; the research literature here is large, trial-driven and reported as what each study measured.
20 profiles · Approved incretin medicines are prescription-only (scheduled) in South Africa and available only through a prescriber; research-grade material is not a medicine and is not for human use.
5-Amino-1MQA small-molecule inhibitor of the enzyme nicotinamide N-methyltransferase (NNMT), studied in obesity and metabolism models.Adipotide (FTPP)A peptidomimetic that targets prohibitin on the blood vessels of white fat and triggers their apoptosis, studied in obese monkeys.AOD-9604A modified C-terminal fragment of human growth hormone (residues 177–191 plus an N-terminal tyrosine) studied for fat metabolism without GH’s growth or glucose effects.CagrilintideA long-acting amylin analogue, studied alone and in a fixed combination with semaglutide (CagriSema).Cardarine (GW501516)A synthetic PPARδ agonist developed for dyslipidaemia and nicknamed an "exercise mimetic" — a doping compound that never became a medicine.DulaglutideA once-weekly GLP-1 receptor agonist made by fusing two GLP-1 analogues to an antibody Fc fragment.In stock · research overviewEloralintideAn investigational, selective, long-acting amylin-receptor agonist from Eli Lilly, studied for obesity.ExenatideA synthetic version of exendin-4, a 39-amino-acid peptide from Gila monster venom and the first GLP-1 receptor agonist approved as a medicine.GLP-1 (Glucagon-Like Peptide-1)The native 30-amino-acid incretin hormone from intestinal L-cells that every GLP-1 receptor agonist imitates.GlucagonThe pancreatic alpha-cell hormone that raises blood glucose — the counter-regulatory partner to insulin and a component of newer multi-agonist research molecules.LiraglutideA once-daily GLP-1 receptor agonist — the first long-acting GLP-1 analogue developed by acylation, predecessor to semaglutide.MazdutideA once-weekly dual GLP-1 / glucagon-receptor agonist, first approved in China in 2025.OrforglipronAn oral, small-molecule (non-peptide) GLP-1 receptor agonist taken once daily without food restrictions.OxyntomodulinA natural 37-amino-acid gut hormone that activates both the GLP-1 and glucagon receptors — the template for the dual-agonist drug class.PramlintideA synthetic analogue of the pancreatic hormone amylin, the first approved amylinomimetic.In stock · research overviewRetatrutideRetatrutide (LY3437943) is a single peptide engineered to activate three receptors at once — GLP-1, GIP and glucagon.SemaglutideA long-acting GLP-1 receptor agonist, the reference molecule of the modern incretin era in both injectable and oral form.SurvodutideA dual glucagon-receptor / GLP-1-receptor agonist being developed for obesity and metabolic liver disease (MASH).TesofensineA triple monoamine (noradrenaline, dopamine, serotonin) reuptake inhibitor that reduced weight in a phase 2 obesity trial.In stock · research overviewTirzepatideTirzepatide is a synthetic dual agonist of the GIP and GLP-1 incretin receptors.
Research reference only — not medical advice, no guidance on human use.